Found 656 hits of Enzyme Inhibition Constant Data Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208929
(US9266878, 155a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CO)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O2/c1-17(33-26-21(25(30)31-16-32-26)14-13-18-7-5-8-19(15-37)34-18)27-35-23-12-6-11-22(29)24(23)28(38)36(27)20-9-3-2-4-10-20/h2-12,16-17,37H,15H2,1H3,(H3,30,31,32,33)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208807
(US9266878, 32a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)nc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C26H18ClF2N9O/c1-13(36-23-18(22(30)34-12-35-23)6-5-14-10-32-26(31)33-11-14)24-37-20-4-2-3-19(27)21(20)25(39)38(24)17-8-15(28)7-16(29)9-17/h2-4,7-13H,1H3,(H2,31,32,33)(H3,30,34,35,36)/t13-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208809
(US9266878, 34a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(N)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C27H19ClF2N8O/c1-14(36-25-20(24(32)34-13-35-25)8-7-18-6-5-17(31)12-33-18)26-37-22-4-2-3-21(28)23(22)27(39)38(26)19-10-15(29)9-16(30)11-19/h2-6,9-14H,31H2,1H3,(H3,32,34,35,36)/t14-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208826
(US9266878, 51a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClN6O/c1-18(33-26-21(25(30)31-17-32-26)16-15-19-9-4-2-5-10-19)27-34-23-14-8-13-22(29)24(23)28(36)35(27)20-11-6-3-7-12-20/h2-14,17-18H,1H3,(H3,30,31,32,33)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208862
(US9266878, 87a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C26H17F3N8O/c1-14(35-24-19(23(30)33-13-34-24)6-5-17-12-31-7-8-32-17)25-36-21-4-2-3-20(29)22(21)26(38)37(25)18-10-15(27)9-16(28)11-18/h2-4,7-14H,1H3,(H3,30,33,34,35)/t14-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208871
(US9266878, 97a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(Cl)c1 |r| Show InChI InChI=1S/C26H18ClFN8O/c1-15(34-24-20(23(29)32-14-33-24)7-6-18-13-30-9-10-31-18)25-35-22-8-5-17(28)12-21(22)26(37)36(25)19-4-2-3-16(27)11-19/h2-5,8-15H,1H3,(H3,29,32,33,34)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208873
(US9266878, 99a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1 |r| Show InChI InChI=1S/C27H18F3N7O/c1-15(35-25-20(24(31)33-14-34-25)11-10-18-9-8-17(29)13-32-18)26-36-22-7-3-6-21(30)23(22)27(38)37(26)19-5-2-4-16(28)12-19/h2-9,12-15H,1H3,(H3,31,33,34,35)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208906
(US9266878, 132a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(cn1)C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H19ClF3N7O/c1-16(26-38-22-9-5-8-21(29)23(22)27(40)39(26)19-6-3-2-4-7-19)37-25-20(24(33)35-15-36-25)13-12-18-11-10-17(14-34-18)28(30,31)32/h2-11,14-16H,1H3,(H3,33,35,36,37)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208934
(US9266878, 160a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(ccn1)C(O)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H20ClN7O3/c1-16(26-35-22-9-5-8-21(29)23(22)27(37)36(26)19-6-3-2-4-7-19)34-25-20(24(30)32-15-33-25)11-10-18-14-17(28(38)39)12-13-31-18/h2-9,12-16H,1H3,(H,38,39)(H3,30,32,33,34)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208824
(US9266878, 49a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cn[nH]c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
PDB
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208901
(US10092563, Compound 58 | US9266878, 127a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1N1CCNCC1 |r| Show InChI InChI=1S/C25H23ClFN9O/c1-15(33-23-18(22(28)31-14-32-23)8-7-17-6-5-16(27)13-30-17)24-34-20-4-2-3-19(26)21(20)25(37)36(24)35-11-9-29-10-12-35/h2-6,13-15,29H,9-12H2,1H3,(H3,28,31,32,33)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208931
(US9266878, 157a)Show SMILES CC(O)c1cccc(n1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H24ClN7O2/c1-17(28-36-24-13-7-11-22(30)25(24)29(39)37(28)20-9-4-3-5-10-20)34-27-21(26(31)32-16-33-27)15-14-19-8-6-12-23(35-19)18(2)38/h3-13,16-18,38H,1-2H3,(H3,31,32,33,34)/t17-,18?/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208821
(US9266878, 46a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc2nc(N)sc2c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H21ClN8OS/c1-16(27-36-22-9-5-8-20(30)24(22)28(39)38(27)18-6-3-2-4-7-18)35-26-19(25(31)33-15-34-26)12-10-17-11-13-21-23(14-17)40-29(32)37-21/h2-9,11,13-16H,1H3,(H2,32,37)(H3,31,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208797
(US9266878, 20b)Show SMILES CC(O)C#Cc1c(N)ncnc1N[C@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C24H19ClF2N6O2/c1-12(34)6-7-17-21(28)29-11-30-22(17)31-13(2)23-32-19-5-3-4-18(25)20(19)24(35)33(23)16-9-14(26)8-15(27)10-16/h3-5,8-13,34H,1-2H3,(H3,28,29,30,31)/t12?,13-/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208817
(US9266878, 42a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cncnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C26H19ClN8O/c1-16(33-24-19(23(28)31-15-32-24)11-10-17-12-29-14-30-13-17)25-34-21-9-5-8-20(27)22(21)26(36)35(25)18-6-3-2-4-7-18/h2-9,12-16H,1H3,(H3,28,31,32,33)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208856
(US9266878, 81-1a | US9266878, 81-2a)Show SMILES COc1cccc(c1C)-n1c(nc2cccc(Cl)c2c1=O)[C@H](C)Nc1ncnc(N)c1C#Cc1ncccc1F |r,wD:21.24,(1.33,8.09,;2.67,7.31,;2.67,5.77,;4,5,;4,3.46,;2.67,2.69,;1.33,3.46,;1.33,5,;,5.78,;,2.69,;,1.15,;-1.33,.38,;-2.67,1.15,;-4,.38,;-5.33,1.15,;-5.33,2.69,;-4,3.46,;-4,5,;-2.67,2.69,;-1.33,3.46,;-1.33,5,;1.33,.38,;2.67,1.15,;1.33,-1.16,;2.67,-1.93,;4,-1.16,;5.33,-1.93,;5.33,-3.46,;4,-4.23,;4,-5.77,;2.67,-3.46,;1.33,-4.24,;,-5.01,;-1.33,-5.78,;-1.33,-7.31,;-2.67,-8.09,;-4,-7.31,;-4,-5.78,;-2.67,-5,;-2.67,-3.46,)| Show InChI InChI=1S/C29H23ClFN7O2/c1-16-23(10-5-11-24(16)40-3)38-28(37-22-9-4-7-19(30)25(22)29(38)39)17(2)36-27-18(26(32)34-15-35-27)12-13-21-20(31)8-6-14-33-21/h4-11,14-15,17H,1-3H3,(H3,32,34,35,36)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208874
(US9266878, 100a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2c(F)cccc2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C26H17F3N8O/c1-14(35-24-20(23(30)33-13-34-24)6-5-17-12-31-7-8-32-17)25-36-22-19(3-2-4-21(22)29)26(38)37(25)18-10-15(27)9-16(28)11-18/h2-4,7-14H,1H3,(H3,30,33,34,35)/t14-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208879
(US9266878, 105a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(C)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C27H20F2N8O/c1-15-5-3-6-21-23(15)27(38)37(19-12-17(28)11-18(29)13-19)26(36-21)16(2)35-25-20(24(30)33-14-34-25)7-8-22-31-9-4-10-32-22/h3-6,9-14,16H,1-2H3,(H3,30,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208883
(US9266878, 109a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C26H19FN8O/c1-16(33-24-18(23(28)31-15-32-24)11-12-21-29-13-6-14-30-21)25-34-20-10-5-9-19(27)22(20)26(36)35(25)17-7-3-2-4-8-17/h2-10,13-16H,1H3,(H3,28,31,32,33)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208896
(US9266878, 122a)Show SMILES COc1cc(F)cc(c1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1N1CCOCC1 |r| Show InChI InChI=1S/C27H25ClFN7O3/c1-16(26-34-22-5-3-4-21(28)23(22)27(37)36(26)35-8-10-39-11-9-35)33-25-20(24(30)31-15-32-25)7-6-17-12-18(29)14-19(13-17)38-2/h3-5,12-16H,8-11H2,1-2H3,(H3,30,31,32,33)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208898
(US9266878, 124a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1C1C[C@@H]2CC[C@H](C1)N2C |r,THB:38:37:30.31.36:34.33| Show InChI InChI=1S/C28H28ClN9O/c1-16(35-26-21(25(30)33-15-34-26)9-6-17-14-31-10-11-32-17)27-36-23-5-3-4-22(29)24(23)28(39)38(27)20-12-18-7-8-19(13-20)37(18)2/h3-5,10-11,14-16,18-20H,7-8,12-13H2,1-2H3,(H3,30,33,34,35)/t16-,18-,19+,20?/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208918
(US9266878, 144a)Show SMILES C[C@H](Nc1ncnc(N)c1C#CC1CCCC1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H25ClN6O/c1-17(32-25-20(24(29)30-16-31-25)15-14-18-8-5-6-9-18)26-33-22-13-7-12-21(28)23(22)27(35)34(26)19-10-3-2-4-11-19/h2-4,7,10-13,16-18H,5-6,8-9H2,1H3,(H3,29,30,31,32)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208924
(US9266878, 150a)Show SMILES CCc1ccnc(c1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H24ClN7O/c1-3-19-14-15-32-20(16-19)12-13-22-26(31)33-17-34-27(22)35-18(2)28-36-24-11-7-10-23(30)25(24)29(38)37(28)21-8-5-4-6-9-21/h4-11,14-18H,3H2,1-2H3,(H3,31,33,34,35)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208931
(US9266878, 157a)Show SMILES CC(O)c1cccc(n1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H24ClN7O2/c1-17(28-36-24-13-7-11-22(30)25(24)29(39)37(28)20-9-4-3-5-10-20)34-27-21(26(31)32-16-33-27)15-14-19-8-6-12-23(35-19)18(2)38/h3-13,16-18,38H,1-2H3,(H3,31,32,33,34)/t17-,18?/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208835
(US9266878, 60a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(c1)-c1ccccc1 |r| Show InChI InChI=1S/C33H23ClFN7O/c1-20(40-31-26(30(36)38-19-39-31)16-15-24-14-13-23(35)18-37-24)32-41-28-12-6-11-27(34)29(28)33(43)42(32)25-10-5-9-22(17-25)21-7-3-2-4-8-21/h2-14,17-20H,1H3,(H3,36,38,39,40)/t20-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208916
(US9266878, 142a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H19ClF3N7O/c1-16(26-38-22-11-5-10-20(29)23(22)27(40)39(26)17-7-3-2-4-8-17)37-25-18(24(33)35-15-36-25)12-13-21-19(28(30,31)32)9-6-14-34-21/h2-11,14-16H,1H3,(H3,33,35,36,37)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208919
(US9266878, 145a)Show SMILES C[C@H](Nc1ncnc(N)c1C#CC1CCCCC1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H27ClN6O/c1-18(33-26-21(25(30)31-17-32-26)16-15-19-9-4-2-5-10-19)27-34-23-14-8-13-22(29)24(23)28(36)35(27)20-11-6-3-7-12-20/h3,6-8,11-14,17-19H,2,4-5,9-10H2,1H3,(H3,30,31,32,33)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208819
(US9266878, 44a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H20ClN7O/c1-17(33-25-20(24(29)31-16-32-25)13-12-18-7-6-14-30-15-18)26-34-22-11-5-10-21(28)23(22)27(36)35(26)19-8-3-2-4-9-19/h2-11,14-17H,1H3,(H3,29,31,32,33)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208826
(US9266878, 51a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClN6O/c1-18(33-26-21(25(30)31-17-32-26)16-15-19-9-4-2-5-10-19)27-34-23-14-8-13-22(29)24(23)28(36)35(27)20-11-6-3-7-12-20/h2-14,17-18H,1H3,(H3,30,31,32,33)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208923
(US9266878, 149a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(ccn1)C(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H20ClF2N7O/c1-16(27-37-22-9-5-8-21(29)23(22)28(39)38(27)19-6-3-2-4-7-19)36-26-20(25(32)34-15-35-26)11-10-18-14-17(24(30)31)12-13-33-18/h2-9,12-16,24H,1H3,(H3,32,34,35,36)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208826
(US9266878, 51a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClN6O/c1-18(33-26-21(25(30)31-17-32-26)16-15-19-9-4-2-5-10-19)27-34-23-14-8-13-22(29)24(23)28(36)35(27)20-11-6-3-7-12-20/h2-14,17-18H,1H3,(H3,30,31,32,33)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208872
(US9266878, 98a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H22N8O/c1-17-7-6-10-22-23(17)27(36)35(20-8-4-3-5-9-20)26(34-22)18(2)33-25-21(24(28)31-16-32-25)12-11-19-15-29-13-14-30-19/h3-10,13-16,18H,1-2H3,(H3,28,31,32,33)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208921
(US9266878, 147a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(C)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O/c1-17-13-14-31-19(15-17)11-12-21-25(30)32-16-33-26(21)34-18(2)27-35-23-10-6-9-22(29)24(23)28(37)36(27)20-7-4-3-5-8-20/h3-10,13-16,18H,1-2H3,(H3,30,32,33,34)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208819
(US9266878, 44a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H20ClN7O/c1-17(33-25-20(24(29)31-16-32-25)13-12-18-7-6-14-30-15-18)26-34-22-11-5-10-21(28)23(22)27(36)35(26)19-8-3-2-4-9-19/h2-11,14-17H,1H3,(H3,29,31,32,33)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208830
(US9266878, 55a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C#N)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H19N9O/c1-17(34-25-21(24(29)32-16-33-25)11-10-19-15-30-12-13-31-19)26-35-22-9-5-6-18(14-28)23(22)27(37)36(26)20-7-3-2-4-8-20/h2-9,12-13,15-17H,1H3,(H3,29,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208849
(US9266878, 74a)Show SMILES CC[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C28H20F4N8O/c1-2-21(38-26-20(25(33)36-14-37-26)7-6-17-13-34-8-9-35-17)27-39-22-5-3-4-19(24(31)32)23(22)28(41)40(27)18-11-15(29)10-16(30)12-18/h3-5,8-14,21,24H,2H2,1H3,(H3,33,36,37,38)/t21-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208851
(US9266878, 76a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H20F2N8O/c1-16(35-25-20(24(30)33-15-34-25)11-10-17-14-31-12-13-32-17)26-36-21-9-5-8-19(23(28)29)22(21)27(38)37(26)18-6-3-2-4-7-18/h2-9,12-16,23H,1H3,(H3,30,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208856
(US9266878, 81-1a | US9266878, 81-2a)Show SMILES COc1cccc(c1C)-n1c(nc2cccc(Cl)c2c1=O)[C@H](C)Nc1ncnc(N)c1C#Cc1ncccc1F |r,wD:21.24,(1.33,8.09,;2.67,7.31,;2.67,5.77,;4,5,;4,3.46,;2.67,2.69,;1.33,3.46,;1.33,5,;,5.78,;,2.69,;,1.15,;-1.33,.38,;-2.67,1.15,;-4,.38,;-5.33,1.15,;-5.33,2.69,;-4,3.46,;-4,5,;-2.67,2.69,;-1.33,3.46,;-1.33,5,;1.33,.38,;2.67,1.15,;1.33,-1.16,;2.67,-1.93,;4,-1.16,;5.33,-1.93,;5.33,-3.46,;4,-4.23,;4,-5.77,;2.67,-3.46,;1.33,-4.24,;,-5.01,;-1.33,-5.78,;-1.33,-7.31,;-2.67,-8.09,;-4,-7.31,;-4,-5.78,;-2.67,-5,;-2.67,-3.46,)| Show InChI InChI=1S/C29H23ClFN7O2/c1-16-23(10-5-11-24(16)40-3)38-28(37-22-9-4-7-19(30)25(22)29(38)39)17(2)36-27-18(26(32)34-15-35-27)12-13-21-20(31)8-6-14-33-21/h4-11,14-15,17H,1-3H3,(H3,32,34,35,36)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208859
(US9266878, 84a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C27H16ClF4N7O/c1-13(37-25-19(24(33)35-12-36-25)5-4-17-3-2-14(29)11-34-17)26-38-23-21(32)7-6-20(28)22(23)27(40)39(26)18-9-15(30)8-16(31)10-18/h2-3,6-13H,1H3,(H3,33,35,36,37)/t13-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208881
(US9266878, 107a)Show SMILES CC[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C27H19F3N8O/c1-2-21(36-25-19(24(31)34-14-35-25)7-6-17-13-32-8-9-33-17)26-37-22-5-3-4-20(30)23(22)27(39)38(26)18-11-15(28)10-16(29)12-18/h3-5,8-14,21H,2H2,1H3,(H3,31,34,35,36)/t21-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208885
(US9266878, 111a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1 |r| Show InChI InChI=1S/C28H20F2N6O/c1-17(34-26-21(25(31)32-16-33-26)14-13-18-7-3-2-4-8-18)27-35-23-12-6-11-22(30)24(23)28(37)36(27)20-10-5-9-19(29)15-20/h2-12,15-17H,1H3,(H3,31,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208892
(US9266878, 118a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1 |r| Show InChI InChI=1S/C25H18ClN9O/c1-15(33-23-18(22(27)31-14-32-23)8-7-16-12-29-10-11-30-16)24-34-20-6-2-5-19(26)21(20)25(36)35(24)17-4-3-9-28-13-17/h2-6,9-15H,1H3,(H3,27,31,32,33)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208909
(US9266878, 135a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(cn1)C(N)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClN8O2/c1-16(27-36-22-9-5-8-21(29)23(22)28(39)37(27)19-6-3-2-4-7-19)35-26-20(24(30)33-15-34-26)13-12-18-11-10-17(14-32-18)25(31)38/h2-11,14-16H,1H3,(H2,31,38)(H3,30,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208926
(US9266878, 152a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1C(C)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H22ClN7O2/c1-17(28-36-24-12-6-11-22(30)25(24)29(39)37(28)19-8-4-3-5-9-19)35-27-21(26(31)33-16-34-27)13-14-23-20(18(2)38)10-7-15-32-23/h3-12,15-17H,1-2H3,(H3,31,33,34,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208928
(US9266878, 154a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(CO)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O2/c1-17(34-26-21(25(30)32-16-33-26)11-10-19-14-18(15-37)12-13-31-19)27-35-23-9-5-8-22(29)24(23)28(38)36(27)20-6-3-2-4-7-20/h2-9,12-14,16-17,37H,15H2,1H3,(H3,30,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208935
(US9266878, 161a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(c1)C(C)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C30H23ClN6O2/c1-18(29-36-25-13-7-12-24(31)26(25)30(39)37(29)22-10-4-3-5-11-22)35-28-23(27(32)33-17-34-28)15-14-20-8-6-9-21(16-20)19(2)38/h3-13,16-18H,1-2H3,(H3,32,33,34,35)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208847
(US9266878, 72a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(C)c2c(=O)n1-c1cccc(c1)C#N |r| Show InChI InChI=1S/C29H20F2N8O/c1-16-6-11-23(31)25-24(16)29(40)39(21-5-3-4-18(12-21)13-32)28(38-25)17(2)37-27-22(26(33)35-15-36-27)10-9-20-8-7-19(30)14-34-20/h3-8,11-12,14-15,17H,1-2H3,(H3,33,35,36,37)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208808
(US9266878, 33a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)nc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C26H20ClN9O/c1-15(34-23-18(22(28)32-14-33-23)11-10-16-12-30-26(29)31-13-16)24-35-20-9-5-8-19(27)21(20)25(37)36(24)17-6-3-2-4-7-17/h2-9,12-15H,1H3,(H2,29,30,31)(H3,28,32,33,34)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208821
(US9266878, 46a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc2nc(N)sc2c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H21ClN8OS/c1-16(27-36-22-9-5-8-20(30)24(22)28(39)38(27)18-6-3-2-4-7-18)35-26-19(25(31)33-15-34-26)12-10-17-11-13-21-23(14-17)40-29(32)37-21/h2-9,11,13-16H,1H3,(H2,32,37)(H3,31,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208855
(US9266878, 80a)Show SMILES COc1cccnc1C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O2/c1-17(34-26-19(25(30)32-16-33-26)13-14-21-23(38-2)12-7-15-31-21)27-35-22-11-6-10-20(29)24(22)28(37)36(27)18-8-4-3-5-9-18/h3-12,15-17H,1-2H3,(H3,30,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Search and Browse
